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Genes for diabetic nephropathy: 
Sweet prospects on the horizon
HH Karnib1,2, S Chua3 and AG Gharavi2
Familial aggregation of diabetic nephropathy has suggested an 
important role for hereditary factors in the development of this trait. 
Österholm et al. provide further evidence that a gene on chromosome 
3q confers susceptibility to this diabetic complication.
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In the past decades, observational cohorts 
and randomized trials have clarifi ed the 
epidemiology of diabetic nephropathy, 
identifying major risk factors for the 
development of this complication. Sev-
eral established risk factors, such as dura-
tion of diabetes, poor glycemic control, 
uncontrolled hypertension, and smok-
ing, increase the risk of kidney disease,1 
whereas improvement in glycemic control 
can delay or reverse lesions of nephropa-
thy.2,3 Nonetheless, there is signifi cant 
interindividual variation in the risk of 
diabetic nephropathy that cannot be 
explained by traditional risk factors: some 
diabetic patients develop diabetic neph-
ropathy despite good glycemic control, 
usually within 20 years of diagnosis of 
diabetes,1,2 whereas many do not develop 
kidney disease despite a long duration of 
diabetes. Studies suggest that much of the 
risk of developing diabetic nephropathy 
may be determined by hereditary fac-
tors. For example, diabetic siblings of a 
patient with diabetic nephropathy have 
a 2.3-fold increased risk of nephropathy 
as compared with siblings of a patient 
without nephropathy.4 Among Pima Indi-
ans, the risk of proteinuria in a diabetic 
individual ranges from 14% to 46% 
depending on whether neither parent, 
one parent, or both parents also have pro-
teinuria.5 Th ese fi ndings have been con-
fi rmed in several observational cohorts 
across diff erent populations; this strongly 
argues for the presence of nephropathy 
susceptibility alleles distinct from those 
conferring risk for diabetes.
Gene identifi cation eff orts for a com-
plex trait such as diabetic nephropathy 
have taken the linkage or the case-control 
association approach.6 Case-control asso-
ciation studies, which, to date, have mostly 
focused on specifi c candidate genes, have 
yielded inconsistent and sometimes con-
fl icting results.6 In the linkage approach, 
one searches for chromosomal regions 
harboring susceptibility genes by study-
ing families segregating the trait of inter-
est. Compared with association studies, 
the linkage approach is not vulnerable 
to population stratification, and until 
recently it was the only design that allowed 
an unbiased, comprehensive survey of the 
genome. However, linkage approaches are 
most successful when large pedigrees that 
segregate genes with large eff ect are avail-
able.7 Large informative families are rarely 
found for most complex traits such as dia-
betic nephropathy, which are determined 
by the interaction of multiple genes, each 
conferring a small eff ect. Th e standard 
linkage approach for complex disorders 
has involved collection of aff ected relative 
pairs (typically sibling pairs) to search for 
genomic regions that show excess shar-
ing among relatives concordant for the 
trait.8 Th is design may not distinguish 
linkage peaks representing susceptibility 
alleles for diabetes or nephropathy, because 
concordant sibs would be expected to 
show excess sharing at loci predisposing 
to either one of these diseases. A variation 
on this approach is the discordant sib-pair 
method, which searches for chromosomal 
regions that show reduced sharing among 
siblings that are concordant for diabetes 
but discordant for nephropathy.9 This 
approach potentially off ers the advantage 
of identifying regions that solely predis-
pose to nephropathy. Th e major limitation 
of the sib-pair design is the requirement 
for large cohorts (potentially thousands of 
subjects) to have suffi  cient power to detect 
loci conferring modest eff ects. Other chal-
lenges include the inability to accurately 
control for covariates such as duration of 
diabetes, variation in glycemic control, 
and antihypertensive therapy among the 
study population. Some of these factors 
may be less problematic in type 1 diabetes 
mellitus, in which disease onset is usually 
marked by the symptoms of acute hyper-
glycemia. Given these limitations, one 
would expect that small- to medium-sized 
sib-pair studies would be underpowered, 
detecting random fl uctuations in test sta-
tistics rather than true positive fi ndings 
that could be independently replicated.
Despite these uncertain odds, several 
groups have bravely taken up the task of 
identifying genes for diabetic nephropa-
thy, and results of several full-genome 
scans are now available. These studies 
have varied designs, and diff erent pheno-
typic criteria have been used, including 
renal failure, proteinuria, and quantita-
tive measures of renal function.8,10–13 As 
expected for a trait with complex architec-
ture, many loci have been reported, and 
most linkage signals have not reached 
genome-wide signifi cance. Interestingly, 
although both proteinuria and renal func-
tion have strong heritable components, 
they seem to be determined by diff erent 
loci.8,10–13 Th us, one may need to further 
distinguish between genes predisposing 
to proteinuria and those predisposing to 
renal failure. Nonetheless, despite varia-
tions in study design, ascertainment crite-
ria, population size, and subject ethnicity, 
some linkage peaks have been detected 
across multiple genome scans, suggesting 
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a true genetic eff ect. A recurring signal in 
linkage studies of diabetic nephropathy, 
when defined as the presence of renal 
failure or macroalbuminuria, resides on 
chromosome 3q. This region was first 
reported when suggestive evidence for 3q 
was found among a cohort of Pima Indi-
ans with type 2 diabetic nephropathy.8 In 
a candidate-gene approach examining 
the angiotensin II type 1 receptor gene 
(AGTR1), evidence for linkage was also 
observed, although AGTR1 was eventually 
excluded as the source of the signal.10 In 
another genome-wide scan in 206 African 
American sib pairs with type 2 diabetes 
and advanced diabetic nephropathy,12 evi-
dence for chromosome 3q was detected 
in the subset of families with the earliest 
onset of renal failure. Th e linkage peaks in 
these studies are broad but do not neces-
sarily overlap, so it is yet unclear whether 
diff erent studies are detecting the same 
signal or whether distinct genes residing 
on chromosome 3q contribute to neph-
ropathy in diff erent populations.
Österholm and colleagues14 (this issue) 
report the results of a genome scan for 
nephropathy in Finnish patients with type 
1 diabetes, providing further evidence for 
a nephropathy susceptibility gene or genes 
on chromosome 3q. Th ey applied the dis-
cordant sib-pair design, studying sibs con-
cordant for type 1 diabetes mellitus but 
discordant for nephropathy, which was 
defi ned by the presence of end-stage renal 
disease or macroalbuminuria. Th e major 
strengths of this study are the uniform 
ethnic background of the patient cohort, 
the robust phenotypic criteria used, and 
the dense panel of markers genotyped in 
the initial genome scan. In addition, the 
authors distinguish themselves by follow-
ing up on all initially suggestive peaks with 
additional markers, thereby maximizing 
information content and rejecting false-
positive peaks. Aft er fi ne mapping, only 
one signal on chromosome 3q remained, 
providing a logarithm of odds (LOD) 
score of 2.67, which is suggestive of link-
age based on published thresholds (that 
is, a LOD score that is expected by chance 
once per genome scan). In addition, 
simulation studies calculating empiric 
thresholds for significance confirmed 
the statistical validity of the observation. 
Th e 3q region reported by Österholm et 
al.14 falls in the vicinity of, but again does 
not exactly coincide with, the previously 
reported loci in Pima Indians, African 
Americans, and white subjects. Th is vari-
ability may be a function of linkage analy-
sis of complex traits, where precise gene 
localization is diffi  cult, or alternatively 
this may indicate the presence of multiple 
genes on 3q that predispose to nephropa-
thy. Further refi nements in phenotyping, 
classifi cation, and analysis may improve 
the ability to resolve this linkage signal. 
Th is issue could also be better examined 
if these different cohorts were pooled 
and analyzed together. Appropriately, the 
authors are cautiously optimistic about 
their fi ndings and suggest that this region 
should be further studied.
How can these findings be pursued 
now? Until a couple of years ago, the 
prospects for identifying genes under-
lying complex traits were fairly gloomy. 
Nowadays, however, the HapMap project 
has provided us with a comprehensive 
catalogue of genetic variation across the 
genome.15 This means that suggestive 
regions can be exhaustively studied to 
identify sequence variants predispos-
ing to complex traits. The underlying 
assumption for these studies is that com-
mon alleles in the population predispose 
to common traits such as diabetic nephro-
pathy, and that these variants can be iden-
tifi ed by case-control association studies.7 
There are now several success stories 
illustrating the power of this strategy. For 
example, an association study pursuing a 
suggestive linkage peak identifi ed variants 
in the TCL72 gene as strong susceptibility 
alleles for type 2 diabetes,16 a fi nding that 
has now been uniformly replicated across 
multiple cohorts.17,18 Th ese association 
studies have greater power in relatively 
isolated populations such as the Finnish, 
where there may be few independent dis-
ease-contributing alleles (founder eff ect). 
Hence the observation of suggestive 
linkage in this population off ers strong 
motivation to pursue the 3q interval by a 
comprehensive case-control association 
study. Moreover, any fi ndings can now 
be pursued in additional well-powered 
cohorts that have now been gathered, 
such as those of the Family Investigation 
of Nephropathy and Diabetes, the Genet-
ics of Kidneys in Diabetes study, and the 
Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Inter-
ventions and Complications study.19–21 
Th ese cohorts can help in the replication 
of results and the assessment of the attrib-
utable risk of specifi c alleles for the devel-
opment of nephropathy across diff erent 
populations. Finally, the development of 
high-throughput genotyping technologies 
now enables the execution of genome-
wide association studies, which have 
a better chance of detecting genes with 
modest eff ects. Th ese studies are under 
way and are expected to yield a catalogue 
of susceptibility alleles for nephropathy 
in the near future, keeping investigators 
busy for good while.
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Vitamin D, insulin resistance, and 
renal disease
A Remuzzi1
Chonchol and Scragg report the results of a population study on 
levels of 25-hydroxyvitamin D in patients with renal dysfunction. They 
demonstrate that these patients do not show vitamin D deficiency 
unless renal function is severely affected (GFR<29 mL/min/1.73m2), 
while vitamin D and renal function loss are independently associated 
with insulin resistance. These data provide more solid evidence than 
previous available studies on small patient groups, and pose new 
questions about the mechanisms responsible for progressive renal 
disease as well as potential effects of vitamin D supplementation.
Kidney International (2007) 71, 96–98. doi:10.1038/sj.ki.5002047
Th e role of vitamin D defi ciency in sev-
eral pathological conditions has been the 
focus of several investigations in the last 
few years.1 Th e complexity of the biologi-
cal role of vitamin D metabolism makes it 
diffi  cult to clearly delineate the role of vita-
min D cascade in these pathophysiological 
systems. More evidence is now emerging 
on the role of vitamin D besides calcium 
and phosphate homeostasis. Th us, vitamin 
D is known also to regulate cell prolifera-
tion and diff erentiation and to modulate 
the immune system, and it is implicated in 
several endocrine functions (Figure 1).2 In 
light of this broad spectrum of biochemi-
cal reactions, and the fact that vitamin D 
is produced by numerous diff erentiated 
cells and tissues,3 it is likely that vitamin 
D is involved in several pathophysiologi-
cal processes. Among these, vitamin D 
seems to be implicated in progressive kid-
ney diseases; however, despite evidence of 
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secondary hyperparathyroidism and 
reduced bone density, there is no direct 
evidence on the mechanisms by which 
vitamin D is involved in the development 
and progression of chronic renal diseases.
According to several reported studies, 
serum levels of vitamin D are decreased 
in patients aff ected by kidney diseases, 
as compared with the general popula-
tion, in diff erent stages of renal-function 
loss.4 However, these studies, although 
they document kidney disease and renal 
function well, are restricted to a small 
number of patients. At variance, the arti-
cle by Chonchol and Scragg5 (this issue) 
provides some interesting data based on 
population data. To overcome the limita-
tions of studies in small groups of patients, 
Chonchol and Scragg collected data from 
the Th ird National Health and Nutrition 
Examination Survey (NHANES III). Th e 
authors clearly demonstrate, by appropri-
ate statistical analysis, that serum levels of 
25-hydroxyvitamin D, a measure of blood 
stores of vitamin D, are eff ectively reduced 
in uremic patients, but only when renal 
function is severely lost (glomerular fi ltra-
tion rate ranging from 15 to 29 ml/min/
1.73 m2) as compared with that of subjects 
with normal renal function, whereas in 
patients aff ected by only mild or moderate 
loss of renal function the serum level of 25-
hydroxyvitamin D is normal. In addition, 
the results of the statistical analysis showed 
that 25-hydroxyvitamin D levels and loss 
of renal function have indepen dent inverse 
associations with insulin resistance,5 sug-
gesting that the relation between vitamin 
D and insulin resistance, if any, still has 
to be elucidated in more detail. Th us, the 
results of this study make some important 
contributions to the understanding of the 
pathophysiological role of vitamin D in 
progressive renal diseases and its possible 
implication for pharmacological therapy. 
In addition, they should guide future 
investigations of the potential role of vita-
min D supplementation.
Th e theoretical possibility that vitamin 
D is involved in the pathophysiology of 
progressive renal disease is based on the 
fact that, besides secondary hyperpar-
athyroidism, this molecule is involved in 
other cellular and metabolic functions 
known to be altered in renal diseases. 
One mechanism that has been better 
